Condition: Cerebral Palsy Infantile · Sponsor: University of Seville
The goal of this clinical trial is to determine whether the use of a mobility platform can improve response time in children with cerebral palsy. The primary question it seeks to answer is: Can the use of a mobility platform enhance cognitive development in children with severe disabilities? Children are randomly assigned to two equal-sized groups: the control group, where participants will continue with their standard therapy, and the intervention group, where participants will use the mobility platform. Researchers will compare outcomes between the two groups. Participants in the control group will engage in a traditional cause-and-effect therapy, using a video that frequently pauses, requiring them to press an adapted button to continue watching. Participants in the intervention group will use the mobility platform during their sessions. Movement begins when the participant presses the adapted button, and the platform advances, adjusting its direction using sensors to detect obstacles. Once the preset time limit is reached, the platform stops, and the child must press the button again to resume movement. This stop-start process mirrors the cause-and-effect training in the control group.
This description comes directly from the study's public registry record.
Félix Biscarri, PhD · +34 954552836 · fbiscarri@us.es
Alberto Molina Cantero, PhD · +34 954552787 · almolina@us.es
Always discuss trial participation with your own doctor first.
| University of Seville | Seville, Andalusia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06616610